Innovation Milestones

Innovating for Life Since 1949

2015

International Launch of MiniMed® 640G

Medtronic launches the MiniMed 640G system, a breakthrough toward an artificial pancreas for people with diabetes, outside the United States (U.S.). The new system incorporates a new insulin pump design to provide convenient diabetes management with a simple user interface, full-color screen, remote bolus, and is waterproof1 in up to 3.6 meters of water for up to 24 hours at a time.
*Not FDA approved or commercially available for sale in the U.S.

2014

Launch of MiniMed® 620G in Japan

Medtronic receives regulatory approval of the MiniMed 620G system in Japan, the country’s first insulin pump with built-in continuous glucose monitoring (CGM) designed to deliver better clinical outcomes for people with diabetes. The system also is the first insulin pump with Japanese-language menus and incorporates a simple user interface, full-color screen, remote bolus, and is waterproof2 in up to 3.6 meters of water for up to 24 hours at a time.
*Not FDA approved or commercially available for sale in the U.S.

2014

Enrollment Begins in Pivotal Study of First Predictive Low Glucose Management Technology

The first patients have been enrolled in an investigational device exemption (IDE) study of Medtronic’s Predictive Low Glucose Management (PLGM) technology. The trial will evaluate the safety of its next-generation integrated insulin pump and CGM system, which automatically stops insulin delivery when the sensor measures sensor glucose level predicted to approach the low limit, and then resumes insulin delivery once sensor glucose levels recover.

2014

Results of OpT2mize Trial Published in The Lancet

The Lancet publishes results of the OpT2mise trial, which shows that MiniMed insulin pumps safely achieve better glucose control for people with insulin-requiring type 2 diabetes than multiple daily injections.3 The largest, global study of its kind, OpT2mise provides strong clinical evidence for expanding access to insulin pump therapy for people with type 2 diabetes with poor glycemic control.

2014

Distribution of i-Port Advance® Injection Port Device

Medtronic gains distribution rights for i-Port Advance, a three-day-wear device that people on insulin injection therapy use to inject insulin into instead of injecting directly into the skin. The product eliminates the need to puncture the skin with each insulin injection and allows Medtronic to meet the needs of a broader group of people with diabetes.

2013

FDA Approval of MiniMed® 530G with Enlite®, First FDA-Approved Artificial Pancreas Device System with Threshold Suspend Automation

FDA approves MiniMed 530G with Enlite, a breakthrough, first-generation artificial pancreas device system with Threshold Suspend automation for people with diabetes 16 years of age or older. The system is the first in the United States that can automatically stop insulin delivery when sensor glucose values reach a preset level and when the patient doesn't respond to the Threshold Suspend alarm. The MiniMed 530G system incorporates the new Enlite sensor, Medtronic's most accurate and comfortable continuous glucose sensor to date with a 31 percent improvement in overall accuracy from the previous generation.4,5,6

2013

ASPIRE Study on Medtronic Insulin Pump with Low Glucose Suspend Published

ASPIRE In-Home study results published in the New England Journal of Medicine and presented at the American Diabetes Association (ADA) 73rd Scientific Sessions.

2012

JDRF Partners with Medtronic to Advance CGM Towards Artificial Pancreas Systems

Medtronic partners with the JDRF, in collaboration with the Helmsley Charitable Trust (HCT), to advance CGM accuracy and reliability towards the next generation artificial pancreas systems. The partnership focuses on accelerating the development of Medtronic’s redundant sensor system to deliver more accurate CGM technology for people with diabetes.

2012

Introduction of mySentry, the First Remote Glucose Monitor

FDA approves the first-of-its-kind mySentry Remote Glucose Monitor, which allows a parent or caregiver to monitor a patient’s MiniMed Paradigm® REAL-Time Revel system from another room. The remote glucose monitor also marks the launch of a new category of Connected Care solutions that will provide people with diabetes and their caregivers convenient options to access their diabetes management information.

2011

FDA Approval of iPro®2 CGM

Medtronic gains FDA approval of and launches iPro2, a next generation professional CGM system that simplifies professional CGM and enables healthcare providers to obtain a more complete picture of glucose control for the patients they treat.

2011

International Launch of Enlite Sensor

The Enlite sensor receives CE approval and is launched in more than 35 countries outside of the U.S., providing international users with a more accurate and comfortable sensor. Enlite marks significant clinical and human factor improvements for CGM, combing greater comfort with improved glucose sensor performance in both overall accuracy and detection of hypoglycemia (low blood glucose).7,8
*FDA approved and commercially available in the U.S. since September 2013.

2010

Medtronic Launches CareLink® Pro 3.0, the First Diabetes Management Software to Offer Advanced Decision Support

CareLink Pro 3.0 Therapy Management Software, the first software program to offer advanced decision support to healthcare professionals managing diabetes, is launched in the United States. The software offers therapy considerations that clinicians can use as a starting point to discuss therapy changes with their patients to help improve glucose control.

2010

STAR 3 Trial Results Confirm Medtronic’s Sensor-Augmented Insulin Pump Therapy Achieves Better Glucose Control than Daily Insulin Injections in People with Diabetes9

STAR 3 study results published in the New England Journal of Medicine and presented at the American Diabetes Association (ADA) 70th Scientific Sessions report adults and children using the Medtronic MiniMed Paradigm REAL-Time System achieved better glucose control without an increase in hypoglycemia (low blood glucose), compared to multiple daily insulin injections (MDI). STAR 3 is the longest and largest randomized, controlled study of sensor-augmented insulin pump therapy in type 1 diabetes.

2010
2010

FDA approval of the MiniMed Paradigm REAL-Time Revel® System

FDA approval of the MiniMed Paradigm REAL-Time Revel system, the second generation of Medtronic’s industry-leading integrated diabetes management system that combines insulin pump therapy, CGM and diabetes therapy management software. The system incorporates new innovative CGM features such as predictive alerts, which can give early warning to people with diabetes to dangerous high or low glucose events up to thirty minutes before they occur so they can take action sooner.

2009

New Diabetes Center in San Antonio Opened

Medtronic opens new customer care and education center in San Antonio, TX for customers and healthcare professionals using Medtronic insulin pumps, CGM and therapy management software for the treatment of diabetes.

2009

International Launch of MiniMed® Veo®, the World's First Step to an Artificial Pancreas

Medtronic receives CE Mark approval of the MiniMed Veo System in more than 50 countries outside of the United States. The new system is the world’s first with Low Glucose Suspend, a feature that automatically stops insulin delivery when sensor glucose levels hit a preset low threshold.
*Not FDA approved or commercially available for sale in the U.S.

2008

FDA Approval of iPro® CGM

FDA approves iPro, a professional CGM system for professional use. This “blinded” CGM system allows healthcare professionals to uncover glucose patterns and trends that often go undetected with fingerstick and A1C testing alone.

2007
2007

Launch of Guardian® REAL-Time System with MiniLink Transmitter and CareLink® Personal Software

Medtronic launches the Guardian REAL-Time system, a stand-alone personal CGM system that provides sensor glucose readings throughout the day as well as alerts to dangerous highs and lows. The new CGM system includes a smaller transmitter that is waterproof up to a depth of 8 feet for up to 30 minutes when connected to the glucose sensor10, and incorporates CareLink Personal Therapy Management Software.

2007

FDA Approves New Medtronic CGM Devices for Children and Teenagers

FDA approves new REAL-Time CGM devices for children and teenagers ages 7 – 17, which was previously only indicated for adults.

2006
2006

FDA Approval of World’s First Integrated Diabetes Management System, the MiniMed Paradigm REAL-Time System

FDA approval of the MiniMed Paradigm REAL-Time system Insulin Pump and CGM system, the first diabetes management integrated system and a major step toward the development of a "closed-loop" insulin delivery system or artificial pancreas that may one day mimic some functions of the human pancreas. The system was indicated for adult patients.

2005

Completion of the GuardControl Trial Using the Guardian REAL-Time CGM System

The GuardControl Trial results published in Diabetes Care report adults and children using Medtronic Guardian REAL-Time CGM achieved better glucose control, compared to fingersticks alone.11 GuardControl is the first international, large-scale, multi-center, randomized clinical outcome trial conducted to evaluate the use of Medtronic’s CGM technology for improved diabetes management for people with type 1 diabetes.

2005
2005

FDA Approval of Guardian RT CGM System

FDA approves Guardian RT CGM system. This patient-use CGM system displays updated real-time glucose values every five minutes and sounds an alarm when sensor glucose levels become too high or too low, helping people with diabetes who desire better glucose control.

2004

Introduction of CareLink Therapy Management Software

Medtronic Diabetes introduces CareLink Therapy Management system for Diabetes, providing people with diabetes with free, secure Web-based software that allows them to identify trends from information downloaded from their insulin pumps.

2004

FDA Approval of Patient-Use Guardian CGM System

The FDA approves the Guardian CGM system, a medical device designed to notify diabetes patients from potentially dangerous high and low glucose fluctuations by sounding an alarm.

2003

FDA Approval of First Wireless Insulin Pump System

Medtronic Diabetes introduces the world's first "intelligent" insulin pump, which wirelessly and automatically transmits a glucose value from the blood glucose meter to the insulin pump, where the Bolus Wizard® calculator recommends proper insulin dosages. The system utilizes a MiniMed Paradigm® 512 Insulin Pump and a Paradigm Link® Blood Glucose Monitor, co-developed with BD (Becton, Dickinson and Company).

2003

CGMS® System Gold® Presented at the American Diabetes Association (ADA)

CGMS system Gold is presented at the American Diabetes Association (ADA) conference. The new system is used by physicians and includes an enhanced glucose sensor, easier to use monitor, and easier to understand graphs and charts to track their patient’s continuous sensor glucose patterns.

2001

Medtronic Acquires MiniMed

MiniMed, Inc. and Medical Research Group (MRG) are combined to create Medtronic MiniMed, Inc., which is headquartered in Northridge, California. As Medtronic's diabetes business unit, the company continues its pioneering leadership in diabetes management with specialties in insulin delivery, CGM, advanced algorithm development and therapy management software.

2001
2001

Introduction of the Quick-set® Infusion Set

The Quick-set infusion set is unveiled, offering customers the most favorable features of existing infusion sets into one product. A low profile disconnect at the infusion site, 90-degree soft cannula, along with a virtually painless insertion at the touch of a button quickly make it our most popular infusion set.

2000

CE Mark Approval for the Next Generation Implantable Insulin Pump

CE mark approval is received for the implantable insulin pump Model 2007-A, enabling the device to be commercially distributed in Europe. This insulin pump is intended for a small subset of people with type 1 diabetes who cannot achieve glucose control through subcutaneous insulin delivery, and delivers insulin through the peritoneal cavity. In March 2003, the U-400 insulin (semi-synthetic insulin) made by Aventis and used with the implantable insulin pump is approved by AFSSAPS, the French regulatory authority.
*Not FDA approved or commercially available for sale in the U.S.

1999
1999

Introduction of the MiniMed® 508 Insulin Pump

The MiniMed 508 insulin pump is introduced, offering new features such as remote programming capabilities to administer or suspend insulin delivery, the ability to program multiple patient-specific delivery patterns, a low volume alert, optional vibrate mode, and child-block.

1999

FDA Approval of the First Physician-Use Glucose Monitoring System

FDA approves the first-ever physician-use CGM system This historical device records glucose values over a 3-day period, after which trend data is downloaded in a healthcare professional's office for analysis. The system is used for establishing a baseline glucose profile, initiating and monitoring therapy, and determining appropriate intervention if a patient is encountering problems with their glucose control.

1996

Start of Clinical Trials for Glucose Sensor

A critical component in ultimately creating a "closed-loop" insulin delivery system, MiniMed glucose sensor moves from the laboratory to actual human clinical trials.

1994

Introduction of Quick Release®

Quick Release is introduced, providing customers with a new level of freedom and flexibility by allowing them to temporarily detach from the insulin pump at the infusion site without having to insert a new infusion set.

1992

Launch of the MiniMed® 506 Insulin Pump

The MiniMed 506 insulin pump is introduced. A major redesign in its programming, electronics and mechanics, the MiniMed 506 delivers advanced features such as meal bolus memory and daily insulin totals.

1987
1987

Introduction of the Sof-set® Infusion Set

The Sof-set infusion set is introduced. The first infusion set to replace the metal needle with a soft flexible cannula, Sof-set represents the maturation of insulin pump therapy and the company's ability to prioritize customer comfort.

1983
1983

Commercialization of the First MiniMed Insulin Pump

MiniMed introduces their first insulin pump, the MiniMed® 502. The 502A soon follows, representing a major technological breakthrough in both size and programmability over the previous model.

1979
1979

Al Mann Becomes Interested in Creating an Insulin Pump

Alfred E. Mann, then the CEO of Pacesetter systems, becomes interested in creating an insulin pump after a conversation with a cardiologist at the University of Alabama, who tells Mann about the severity of heart problems due to diabetes.

1949

Development of the First Battery Operated Pacemaker

After evolving from simply repairing medical equipment to improving it, Medtronic is approached by Dr. Lillehei at the University of Minnesota Medical School about his need for better pacemakers. Earl Bakken and his team create the first wearable, battery-operated pace maker, a leap forward for cardiac care and the launch of Medtronic's journey to become the world's leading medical device company.

1949

The Founding of Medtronic

Earl Bakken and his brother-in-law, Palmer Hermundslie, begin a medical equipment repair shop in Earl's garage.